Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Free Cash Flow: 2021-2025

Historic Free Cash Flow for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.6 million.

  • InMed Pharmaceuticals' Free Cash Flow rose 12.00% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 13.70%. This contributed to the annual value of -$7.8 million for FY2025, which is 11.03% down from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Free Cash Flow is -$1.6 million, which was up 9.61% from -$1.8 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Free Cash Flow high stood at -$689,750 for Q2 2023, and its period low was -$5.4 million during Q1 2022.
  • Moreover, its 3-year median value for Free Cash Flow was -$1.8 million (2025), whereas its average is -$1.7 million.
  • Per our database at Business Quant, InMed Pharmaceuticals' Free Cash Flow spiked by 82.96% in 2023 and then crashed by 72.81% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$3.3 million in 2021, then grew by 18.26% to -$2.7 million in 2022, then skyrocketed by 31.88% to -$1.8 million in 2023, then tumbled by 35.39% to -$2.5 million in 2024, then increased by 12.00% to -$1.6 million in 2025.
  • Its Free Cash Flow stands at -$1.6 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$1.7 million for Q1 2025.